DORADO 2009

NCT00330369

1 Treatments

Studied treatment  darusentan 50 mg, 100 mg or 300 mg

Control treatment  placebo

Concomittant treatments  -

2 Patients

Patients  patients with treatment-resistant hypertension

Inclusion criteria  patients with systolic blood pressure of 140 mm Hg or more (>=/=130 mm Hg if patient had diabetes or chronic kidney disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at full or maximum tolerated doses

Exclusion criteria  -

3 Methods

Blinding  double blind

Design  Parallel groups

Centers  117

Geographical area  North and South America, Europe, New Zealand, Australia

Sizes  247/132

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References